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diabetes: an updated national estimate of
prevalence based on Kidney Disease: Improving
Global Outcomes (KDIGO) staging
Robert A Bailey1*, Yiting Wang2, Vivienne Zhu2 and Marcia FT Rupnow1Abstract
Background: Kidney Disease Improving Global Outcomes (KDIGO) 2013 updated the classification and risk
stratification of chronic kidney disease (CKD) to include both the level of renal function and urinary albumin
excretion (UAE). The update subclassifies the previous category of moderate renal impairment. There is currently
limited information on the prevalence of CKD based on this new classification in United States (US) adults with type 2
diabetes mellitus (T2DM). The objective of this study was to provide such estimates, for T2DM both overall and in
those≥ 65 years of age. We used the continuous National Health and Nutrition Examination Survey (NHANES)
1999–2012 to identify participants with T2DM. Estimated glomerular filtration rate (eGFR) and UAE were calculated
using laboratory results and data collected from the surveys, and categorized based on the KDIGO classification.
Projections for the US T2DM population were based on NHANES sampling weights.
Results: A total of 2915 adults diagnosed with T2DM were identified from NHANES, with 1466 being age≥ 65 years.
Prevalence of CKD based on either eGFR or UAE was 43.5% in the T2DM population overall, and 61.0% in those
age≥ 65 years. The prevalence of mildly decreased renal function or worse (eGFR < 60/ml/min/1.73 m2) was 22.0%
overall and 43.1% in those age≥ 65 years. Prevalence of more severe renal impairment (eGFR < 45 ml/min/1.73 m2)
was 9.0% overall and 18.6% in those age≥ 65 years. The prevalence of elevated UAE (> 30 mg/g) was 32.2% overall
and 39.1% in those age≥ 65 years. The most common comorbidities were hypertension, retinopathy, coronary heart
disease, myocardial infarction, and congestive heart failure.
Conclusions: This study confirms the high prevalence of CKD in T2DM, impacting 43.5% of this population. Additionally,
this study is among the first to report US prevalence estimates of CKD based on the new KDIGO CKD staging system.
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AlbuminuriaBackground
Type 2 diabetes mellitus (T2DM) is the leading cause of
chronic kidney disease (CKD) in the United States (US),
with previous estimates suggesting close to 40% of patients
with T2DM having evidence of CKD [1]. Concordant with
the high prevalence of CKD in this population, diabetes
was attributed as the cause of end-stage renal disease
(ESRD) in 44.2% of incident dialysis patients in 2011 [2].* Correspondence: rbailey5@its.jnj.com
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unless otherwise stated.The high burden of CKD in T2DM and the associated
adverse outcomes result in high health-care costs to both
public and private payers [2,3].
Based on the significant impact of CKD, Kidney Disease
Outcomes Quality Initiative (KDOQI) and Kidney Disease:
Improving Global Outcomes (KDIGO) recommend a focus
on early identification of CKD. This early identification may
allow for treatment directed at CKD to slow or prevent
progression, and treatment of associated complications and
comorbidities such as cardiovascular disease [4,5].td. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
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classification system based on estimated glomerular filtra-
tion rate (eGFR) [5]. The original classification ranged
from Stage 1 CKD (defined as normal kidney function
with other markers for kidney damage) to Stage 5 CKD
(defined as kidney failure). This staging system served to
provide clinicians with stage-specific action plans for treat-
ment of CKD and associated comorbidities and complica-
tions. Additionally, this staging system facilitated research
and served as a framework for developing a public-health
approach to CKD.
Soon after the original KDOQI CKD staging system was
published, Go et al. [6] reported that although the risk for
death, cardiovascular disease, and hospitalizations
increased when eGFR declined below 60 ml/min/1.73 m2
(Stage 3 CKD), these risks substantially increased when
eGFR declined below 45 ml/min/1.73 m2 [6]. Based on
this evidence, Go et al. advocated for subclassification of
Stage 3 to reflect these findings. A recent meta-analysis
provided further evidence to support the division of Stage
3 CKD into 3a and 3b based on the increased risk for
progression to ESRD, and cardiovascular and all-cause
mortality at the GFR threshold of < 45 ml/min/m2 [7,8].
Based on this new evidence, developed since KDOQI,
KDIGO recently updated the classification system for
CKD [4]. This new classification system is based on the
cause of CKD, gFR category, and albuminuria category
(CGA). The cause category is based on the presence or
absence of systemic disease. The GFR categories acknow-
ledge the need to subdivide Stage 3 CKD, classified as G3
under the new classification system, into G3a (eGFR 45–
59) and G3b (eGFR 30–44). The albuminuria categories
are based on the presence and severity of albuminuria.
This new classification was developed to allow risk stratifi-
cation based on progression of CKD and cardiovascular
and all-cause mortality.
The prevalence of diabetes in the older adult population
(age > 65) is greater than 20%. This older adult group also
has a higher prevalence of comorbid conditions (such
hypertension, cardiovascular disease, and CKD) compared
to younger populations [2,9]. Based on these specific
considerations in the older adult population, the American
Diabetes Association (ADA) recommends a different
approach in this population. These specific recommenda-
tions include potentially less stringent treatment targets
and special consideration in the selection of antihypergly-
cemic agents.
To date, there are no US estimates of the prevalence
of CKD in T2DM based on this new classification sys-
tem, particularly for stages G3a and G3b. The objective
of this study was to provide current national estimates
of the prevalence of CKD in the overall T2DM popula-
tion, and in the subpopulation aged ≥ 65 years using this
new KDIGO classification.Methods
National Health and Nutrition Examination Survey
(NHANES) 1999–2012 data were used for this study.
NHANES is a cross-sectional survey designed to monitor
the health and nutritional status of the civilian non-
institutionalized US population [10]. NHANES data include
demographics, comorbidities, and medications that were
reported by the survey participants during a home inter-
view. Additionally, standardized physical examinations and
laboratory tests were conducted in mobile examination
centers. This study was exempt from the requirement of an
Institutional Review Board since this research was based on
data that were available from a publicly available source.
NHANES participants with T2DM were identified using
previously published criteria to differentiate T2DM from
type 1 diabetes mellitus (T1DM) [11,12]. The criteria used
were: self-reported diagnosis of diabetes or “sugar diabetes”
at age ≥ 30 years, not initiating insulin therapy within 1 year
of diagnosis, and not pregnant (women) at the time of
interview and examination. We focused on diagnosed
diabetes with an aim to help health-care providers and
population health managers to understand CKD and plan
preventive management for their patients known to have
T2DM; strategies for prediabetes and undiagnosed diabetes
(such as by the criteria of hemoglobin A1c above 6.5% or
single fasting plasma glucose measure above 180 mg/dl) are
likely to be different. Since evidence suggests that the
prevalence of reduced GFR, albuminuria, and micro/
macrovascular complications differs between T1DM and
T2DM [13], we made an effort to identify and exclude
those with T1DM.
Comorbidities were determined based on participant
self-reporting of diagnosis by a doctor or other health-care
professional. The identification of hypertension was add-
itionally based on measured mean systolic blood pressure/
diastolic blood pressure > 140/90 mmHg, or self-reported
use of antihypertensive agents, including diuretics, beta-
blockers, calcium-channel blockers, angiotensin-converting
enzyme (ACE) inhibitors, angiotensin receptor blockers, or
other antihypertensive agents (including alpha-1-blockers,
central alpha-2-agonists, direct vasodilators, renin inhibitors,
and other centrally acting drugs).
To ensure comparability with standard lab assays and
consistency when testing methods or instruments change
across different survey cycles, NHANES conducts quality
assurance and monitoring, and provides specific calibration
recommendations in analytical notes for affected lab tests
and survey cycles [10]. Serum creatinine levels measured
from the 1999–2000, and 2005–2006 survey cycles were
calibrated according to NHANES recommended equations
to be traceable to an isotope dilution mass spectrometry
(IDMS) reference method (calibration not needed for the
other survey years in this study). Similarly, urine creatinine
measures before the 2007–2008 surveys were corrected
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with the 2007–2008 survey and forward. Spot urine albu-
min was measured and tested consistently across 1999–
2012 survey cycles. Urinary albumin to creatinine ratio
(UACR) was calculated by taking the ratio between urinary
albumin and urinary creatinine and expressed as mg/g [14].
CKD was categorized based on the new KDIGO classifi-
cation recommendations [4]. GFR categories were based
on eGFR: G1 ≥ 90 ml/min/1.73 m2 (normal to high), G2
60–89 ml/min/1.73 m2 (mildly decreased), G3a 45–59 ml/
min/1.73 m2 (mildly to moderately decreased), G3b 30–
44 ml/min/1.73 m2 (moderately to severely decreased), G4
15–29 ml/min/1.73 m2 (severely decreased), and G5 <
15 ml/min/1.73 m2 (kidney failure). Albuminuria catego-
ries were based on the UACR: A1 < 30 mg/g (normal to
mildly increased), A2 30–300 mg/g (moderately
increased), and A3 > 300 mg/g (severely increased). eGFR
was calculated using the Chronic Kidney Disease
Epidemiology Collaboration (CKD-EPI) equation [14].
Because some practitioners and institutions may still use
the Modification of Diet in Renal Disease (MDRD) equa-
tion [15], eGFR using this equation was also calculated
and reported.
To provide an estimate of the US prevalence of CKD in
the overall and age ≥ 65 years T2DM population, the obser-
vations from the NHANES were weighted to account for
the complex design of NHANES [16] and age-adjusted to
the 2012 US diabetes population according to the National
Health Interview Survey (NHIS) [17,18]. Statistical analyses
were performed using survey procedures in SAS version 9.2
(SAS Institute, Cary, North Carolina, USA). We performed
linear trend tests on the projected mean eGFR and UACR
values, as well as prevalence of the eGFR and UACR
categories by the KDIGO classification. Two-sided p values
of < 0.05 were considered statistically significant.Results
A total of 2915 adults with T2DM were identified from
NHANES 1999–2012. We combined the NHANES 1999–
2012 data because none of the linear trend tests for eGFR
and UACR were statistically significant, and numerical
values also appeared comparable across these survey cycles
(data not shown). The sample demographics and projected
national estimates are presented in Table 1. Based on the
national estimates, the mean standard error (SE) age of the
US T2DM population was 61.4 (0.4) years, with 50.3% age ≥
65 years. The mean (SE) duration of T2DM was 9.7 (0.1)
years. Non-Hispanic whites comprised 62.6% of the study
population, non-Hispanic blacks 15.9%, and Mexican
Americans 8.1%. The most common self-reported comor-
bidities were hypertension (71.9%), retinopathy (20.9%),
coronary heart disease (12.5%), myocardial infarction
(12.0%), and congestive heart failure (10.6%).The national estimate of mean (SE) eGFR (CKD-EPI) for
the T2DM population was 80.5 (0.5) ml/min/1.73 m2, and
the mean (SE) urinary albumin excretion (UAE) was 109.1
(1.4) mg/g. The overall prevalence of CKD based on either
eGFR (CKD-EPI) or albuminuria criteria was 43.5%, with
95% confidence interval (CI) 41.6-45.4%. The prevalence of
mildly decreased to more severe renal impairment based
on eGFR below the threshold of 60 ml/min/1.73 m2 was
22% (95% CI 20.4-23.5%). Based on the new subdivision of
stage 3 CKD into 3a/3b, the prevalence of Stage 3a CKD
(eGFR > 45–59 ml/min/1.73 m2) was 12.9% (95% CI 11.5-
14.3%) (Table 2) and Stage 3b or lower (eGFR < 45 ml/min/
1.73 m2) was 9% (95% CI 7.8-10.3%). The prevalence of
elevated UAE based on UACR ≥ 30 mg/g was 32.2% (95%
CI 30.0-34.3%), 24.4% (95% CI 22.3-26.4%) with moderately
increased (UACR ≥ 30–300 mg/g) and 7.8% (95% CI 6.5-
9.1%) with severely increased (UACR > 300 mg/g) UAE.
Using MDRD to calculate eGFR, the mean (SE) eGFR
was 79.1 (0.6) ml/min/1.73 m2. The overall prevalence of
CKD using either eGFR (MDRD) or albuminuria criteria
was 45.1%, 95% CI 43.0-47.1%. The prevalence of mildly
decreased to more severe renal impairment based on
eGFR below the threshold of 60 ml/min/1.73 m2 was
24.0%, 95% CI 22.1-26.0%; 14.9% (95% CI 13.2-16.6%) had
eGFR (MDRD) 45–59 ml/min/1.73 m2 (Table 3) and 9.2%
had eGFR (MDRD) < 45 ml/min/1.73 m2.
A total of 1466 NHANES participants were aged ≥
65 years, representing 50.3% of the analysis sample. The
projected mean (SE) age for this population was 73.4 (0.1)
years, and the mean (SE) diabetes duration was 12.9 (0.3)
years. Non-Hispanic whites comprised 72.6% of the study
population age ≥ 65 years, non-Hispanic blacks 12.4%, and
Mexican Americans 5.0%. The most common self-reported
comorbidities were hypertension (80.9%), retinopathy (22.2%),
coronary heart disease (19.9%), myocardial infarction (18.2%),
and congestive heart failure (16.9%).
For the age ≥ 65 years subgroup, the prevalence of CKD
using either eGFR (CKD-EPI) or albuminuria criteria was
61.0%, 95% CI (57.9- 64.1%). The prevalence of mildly
decreased to more severe renal impairment based on eGFR
(CKD-EPI) below the threshold of 60 ml/min/1.73 m2 was
43.1% (95% CI 39.5-46.6%). Stage G3a (eGFR 45–59 ml/
min/1.73 m2) represented 24.5% (95% CI 21.6-27.4%)
(Table 4), and eGFR < 45 ml/min/1.73 m2 was 18.6% (95%
CI 15.9-21.2%). The prevalence of increased UAE based on
UACR ≥ 30 mg/g was 39.1% (95% CI 36.3-41.8%). Mode-
rately increased UAE (ACR 30–300 mg/g) was present in
29.3% (95% CI 26.4-32.2%), and severely increased UAE
(ACR > 300 mg/g) was present in 9.8% (95% CI 7.5-12.0%).
Using MDRD to calculate eGFR in the age ≥ 65 years
subgroup, the mean (SE) eGFR was 64.8 (0.8) ml/min/
1.73 m2. The overall prevalence of CKD using either eGFR
(MDRD) or albuminuria criteria was 61.8% (95% CI 58.5-
65.0%). The prevalence of mildly decreased to more severe
Table 1 Demographic characteristics
Variable Overall Age ≥ 65 years
NHANES Projected national estimate NHANES Projected national estimate
N = 2915 N = 1466
Mean (SE) age, years 63.9 (0.2) 61.4 (0.4) 73.4 (0.1) 73.1 (0.1)
Age≥ 65 years, % (n) 50.3 (1466) 40.3 (N/A) 100 (1466) 100 (N/A)
Sex, % male (n) 52.0 (1517) 50.8 (N/A) 51.8 (760) 47.1 (N/A)
Mean (SE) diabetes duration, years 10.7 (0.2) 9.7 (0.2) 13.2 (0.3) 12.9 (0.3)
Mean (SE) eGFR (CKD-EPI), ml/min/1.73 m2 78.2 (0.5) 80.5 (0.5) 65.3 (0.6) 64.2 (0.8)
Mean (SE) eGFR (MDRD), ml/min/1.73 m2 78.5 (0.5) 79.1 (0.6) 66.7 (0.6) 64.8 (0.8)
Mean (SE) UAE, mg/g 109.7 (1.3) 109.1 (1.4) 103.4 (1.6) 99.1 (1.8)
Race/ethnicity
Mexican American, % (n) 21.9 (638) 8.1 (N/A) 18.4 (269) 5.0 (N/Aa)
Other Hispanic, % (n) 7.9 (231) 5.9 (N/A) 6.0 (88) 3.4 (N/Aa)
Non-Hispanic white, % (n) 37.9 (1105) 62.6 (N/A) 47.0 (689) 72.6 (N/Aa)
Non-Hispanic black, % (n) 26.5 (773) 15.9 (N/A) 23.1 (338) 12.4 (N/Aa)
Other, including multiracial, % (n) 5.8 (168) 7.4 (N/A) 5.6 (82) 6.5 (N/Aa)
Comorbidities (self-reported)
Hypertension, % (n)a 74.0 (2157) 71.9 (N/A) 80.3 (1177) 80.9 (N/Aa)
Retinopathy, % (n) 22.1 (645) 20.9 (N/A) 23.1 (339) 22.2 (N/Aa)
Coronary heart disease, % (n) 12.0 (351) 12.5 (N/A) 16.6 (243) 19.9 (N/Aa)
Myocardial infarction, % (n) 12.7 (371) 12.0 (N/A) 16.5 (241) 18.2 (N/Aa)
Congestive heart failure, % (n) 11.2 (326) 10.6 (N/A) 15.5 (227) 16.9 (N/Aa)
Angina, % (n) 9.0 (261) 9.5 (N/A) 11.4 (167) 13.9 (N/Aa)
Stroke, % (n) 10.1 (293) 9.1 (N/A) 13.6 (200) 14.4 (N/Aa)
aN = 21,318,626 based on the total number of persons with diabetes who were age ≥ 18 years, NHIS 2012.
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threshold of 60 ml/min/1.73 m2 was 44.2% (95% CI 40.3-
48.1%); 26.1% had eGFR 45–59 ml/min/1.73 m2 (95% CI
22.9-29.3%) (Table 5), and 18.1% (95% CI 15.5-20.8%) had
eGFR < 45 ml/min/1.73 m2.Table 2 eGFR (CKD-EPI) and UACR category prevalence of CK
GFR category,
ml/min/1.73 m2 (CKD-EPI) < 30 30
N % (95% CI) N
G1≥ 90 733b 29.1 (27.0-31.2) 269
G2 60-89 753b 27.4 (25.1-29.6) 282
G3a 45-59 242 8.0 (6.9-9.2) 132
G3b 30-44 84 2.7 (2.1-3.3) 75
G4 15-29 20 0.6 (0.2-0.9) 33
G5 < 15 d 0.0 (0.0-0.1) d
Column N, % (95% CI)c 1834 67.8 (65.7-70.0) 792 2
aAge adjusted to 2012 NHIS diabetes population.
bDoes not meet CKD criteria based on eGFR or albuminuria.
cSum of rows and columns may deviate due to rounding.
dCell frequency suppressed when count < 3 to avoid potential identifiability and imDiscussion
Based on a nationally representative sample, this report is
the first to provide estimates of the prevalence of CKD in
the US population with T2DM based on the new KDIGO
classification. These new estimates provide insights on theD in T2DMa
Albuminuria category, mg/g
-300 > 300 Rowc
% (95% CI) N % (95% CI) N % (95% CI)
9.2 (7.8-10.5) 56 1.4 (0.9-1.9) 1058 39.7 (37.4-42.0)
8.4 (7.0-9.7) 92 2.6 (1.9-3.2) 1127 38.3 (35.7-40.9)
3.6 (2.8-4.3) 49 1.4 (0.8-1.9) 423 12.9 (11.5-14.3)
2.1 (1.5-2.6) 36 1.0 (0.5-1.5) 195 5.8 (4.8-6.8)
1.2 (0.6-1.7) 36 1.0 (0.5-1.6) 89 2.8 (2.0-3.6)
0.0 (0.0-0.0) 20 0.4 (0.1-0.6) 23 0.4 (0.2-0.7)
4.4 (22.3-26.4) 289 7.8 (6.5-9.1) 2915 100 (N/A)
precision of estimates.




< 30 30-300 > 300 Rowc
N % (95% CI) N % (95% CI) N % (95% CI) N % (95% CI)
G1≥ 90 629b 22.9 (20.7-25.1) 239 7.4 (6.1-8.6) 46 1.2 (0.7-1.7) 914 31.4 (28.9-34.0)
G2 60-89 834b 32.1 (29.4-34.7) 305 9.8 (8.3-11.3) 97 2.7 (2.0-3.3) 1236 44.6 (41.7-47.5)
G3a 45-59 267 9.6 (8.2-11.0) 141 4.0 (3.0-4.9) 51 1.4 (0.8-1.9) 459 14.9 (13.2-16.6)
G3b 30-44 88 2.9 (2.2-3.7) 74 2.1 (1.5-2.6) 40 1.2 (0.7-1.7) 202 6.2 (5.1-7.2)
G4 15-29 15 0.4 (0.2-0.5) 32 1.2 (0.6-1.7) 35 1.0 (0.4-1.6) 82 2.5 (1.8-3.2)
G5 < 15 d 0.0 (0.0-0.0) d 0.0 (0.0-0.0) 20 0.4 (0.1-0.6) 22 0.5 (0.1-0.7)
Column N, % (95% CI)c 1834 67.8 (65.7-70.0) 792 24.4 (22.3-26.4) 289 7.8 (6.5-9.1) 2915 100 (N/A)
aAge adjusted to 2012 NHIS diabetes population.
bDoes not meet CKD criteria based on eGFR or albuminuria.
c Sum of rows and columns may deviate due to rounding.
dCell frequency suppressed when count < 3 to avoid potential identifiability and imprecision of estimates.
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albuminuria categories. A recent report by Plantinga et al.
[19] using NHANES 1999–2006 and a similar staging of
CKD reported a slightly lower prevalence of CKD than
this study. The Plantinga et al. report was based on a
smaller sample size (the more recent NHANES data were
not available at the time of their study) with a lower mean
age, and did not attempt to exclude T1DM or those diag-
nosed with T2DM age < 30 years. A previous report by
Coresh et al. [20] observed that the prevalence of CKD
increased with age, suggesting that the criteria used for
this study may explain some of the differences observed.
Additionally, the previous report did not provide the
distribution of albuminuria categories as it predated the
new KDIGO classification.
Another recent report on the prevalence of CKD in
diabetes based on NHANES 2005–2010 observed a lower
prevalence of CKD [2]. This analysis included both T1DM
and T2DM, and included NHANES participants age ≥
20 years, which may explain the differences in CKDTable 4 Age ≥ 65 years: eGFR (CKD-EPI) and ACR category pre
GFR category,
ml/min/1.73 m2 (CKD-EPI) < 30 30
N % (95% CI) N
G1≥ 90 120b 6.0 (4.7-7.3) 54
G2 60-89 448b 33.0 (30.3-35.8) 187 1
G3a 45-59 197 14.8 (12.6-17.0) 111
G3b 30-44 69 5.6 (4.2%-7.0) 68
G4 15-29 19 1.4 (0.6-2.2) 28
G5 < 15 d 0.1 (−0.1-0.2) d
Column N, % (95% CI)c 854 60.9 (58.2-63.7) 449 2
aAge adjusted to 2012 NHIS diabetes population.
bDoes not meet CKD criteria based on eGFR or albuminuria.
cSum of rows and columns may deviate due to rounding.
dCell frequency suppressed when count < 3 to avoid potential identifiability and imprevalence observations. Additionally, the analysis did not
report details regarding the severity of albuminuria.
Consistent with previous reports, the overall preva-
lence of CKD based on eGFR was lower using CKD-EPI
compared to MDRD [21,22]. Based on the evidence that
CKD-EPI is more accurate than MDRD for estimating
kidney function and predicting risk of mortality and
ESRD (KDIGO), CKD-EPI is now the recommended
equation. We chose to report eGFR based on MDRD as
well, as this equation may still be in use by some clini-
cians and institutions [23].
The prevalence of CKD in the age ≥ 65 years population
was higher than in the overall T2DM population. This is
consistent with previous reports of increasing prevalence
of CKD [20] and incidence of ESRD [24] with age. The
prevalence of comorbidities such as hypertension, retino-
pathy, and cardiac disease was higher in the age ≥ 65 years
population compared to the overall population.
The recognition of the presence of CKD and classifica-
tion based on the severity of CKD was first proposed byvalence of CKD in T2DMa
Albuminuria category, mg/g
-300 > 300 Rowc
% (95% CI) N % (95% CI) N % (95% CI)
3.2 (2.2-4.1) 7 0.2 (0.0-0.3) 181 9.4 (7.9-10.9)
1.5 (9.5-13.6) 51 3.1 (2.0-4.1) 686 47.6 (44.4-50.8)
7.5 (5.9-9.2) 35 2.2 (1.2-3.2) 343 24.5 (21.6-27.4)
4.4 (3.2-5.7) 31 2.1 (1.0-3.3) 168 12.2 (10.0-14.4)
2.7 (1.4-4.0) 29 2.0 (0.9-3.1) 76 6.1 (4.5-7.8)
0.0 (0.0-0.0) 10 0.2 (0.0-0.4) 12 0.3 (0.1-0.5)
9.3 (26.4-32.2) 163 9.8 (7.5-12.0) 1466 100 (N/A)
precision of estimates.




< 30 30-300 > 300 Rowc
N % (95% CI) N % (95% CI) N % (95% CI) N % (95% CI)
G1≥ 90 136b 6.5 (5.3-7.7) 71 4.3 (3.2-5.4) 11 0.6 (0.1-1.1) 218 11.4 (9.9-12.9)
G2 60-89 427b 31.7 (28.7-34.8) 168 10.1 (8.1-12.1) 46 2.5 (1.6-3.5) 641 44.4 (40.8-48.0)
G3a 45-59 205 15.8 (13.4-18.2) 116 7.9 (6.2-9.7) 37 2.4 (1.3-3.4) 358 26.1 (22.9-29.3)
G3b 30-44 72 6.1 (4.5-7.7) 66 4.3 (3.1-5.5) 31 2.1 (1.0-3.3) 169 12.5 (10.3-14.8)
G4 15-29 14 0.8 (0.4-1.3) 27 2.6 (1.3-3.9) 28 2.0 (0.9-3.1) 69 5.4 (3.9-6.9)
G5 < 15 d 0.0 (0.0-0.0) d 0.0 (0.0-0.0) 10 0.2 (0.0-0.4) 11 0.2 (0.1-0.4)
Column N, % (95% CI)c 854 60.9 (58.2-63.7) 449 29.3 (26.4-32.2) 163 9.8 (7.5-12.0) 1466 100 (N/A)
aAge adjusted to 2012 NHIS diabetes population.
bDoes not meet CKD criteria based on eGFR or albuminuria.
cSum of rows and columns may deviate due to rounding.
dCell frequency suppressed when count < 3 to avoid potential identifiability and imprecision of estimates.
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stage-specific treatment recommendations [4,5] and allow
determination of risk of progression to ESRD and morta-
lity. Both diabetes-specific and more general treatment
recommendations were given. The importance of the
inclusion of the level of albuminuria in making treatment
decisions was recently emphasized by the results of a
meta-analysis by Lv et al. [25]. Consideration of kidney
function within the categories 3a and 3b when making
diabetes- and non-diabetes-related treatment decisions
has recently been emphasized [4,26]. Medication-related
considerations include the potential for decreased ability
to excrete drugs and/or their metabolites, increased sensi-
tivity to medications (e.g. those bound to albumin), dimi-
nished tolerance of side effects, or loss of efficacy. The
importance of the level of kidney function within categories
3a and 3b is highlighted in KDIGO for metformin, where a
review of its continued use is recommended when a patient
transitions from category G3a to G3b [4]. Other manage-
ment-related considerations at the transition of category 3a
to 3b CKD include the frequency of recommended moni-
toring and evaluation for evidence of metabolic bone
disease [4]. This current analysis, which includes informa-
tion related to the severity of albuminuria and the distribu-
tion of CKD within categories 3a and 3b, is informative to
health-care providers, payers, and policy makers when
making decisions on treatment choices and population-
based interventions for patients diagnosed with T2DM to
potentially prevent the progression of CKD and to
minimize the impact of associated complications.
The information related to the T2DM population aged ≥
65 years may be relevant to those who provide care and
make decisions specifically for this population, such as
Medicare Part D pharmacy benefit plans. The relevance of
this information in this older adult group is highlighted
in the ADA 2014 standards of care [9], where there are
specific considerations for AHA drug classes such asmetformin, thiazolidinediones, insulin secretagogues (such
as sulfonylureas), and insulin.
This study has several limitations. We focused specifi-
cally on T2DM, and therefore made an attempt to exclude
NHANES participants with T1DM based on previously
reported methodologies. The empirical algorithm based
on age at diabetes onset and early initiation of insulin the-
rapy may exclude younger-onset T2DM patients and
include older-onset T1DM patients. The determination of
the presence of kidney disease based on eGFR and albu-
minuria was made based on a single random sample of
the laboratory values, so the chronicity of the observations
could not be determined. The cause of CKD could not be
determined based on the data collected in NHANES, so
we could not categorize CKD according to the cause
category of the new KDIGO classification. Due to the
cross-sectional nature of NHANES, outcomes such as
CKD progression and mortality could not be assessed.Conclusions
This study confirms the high prevalence of CKD in
T2DM, with 43.5% of individuals having evidence of
CKD, and provides insights into prevalence of all CKD
categories based on the new KDIGO staging system. The
prevalence of more severe impairment of renal function,
defined as eGFR < 45 ml/min/1.73 m2, impacts < 10% of
T2DM patients. This study also provides estimates of the
distribution of albuminuria by severity within the catego-
ries of eGFR, providing insights into the distribution of
risk categories for progression to ESRD and mortality.
Additionally, this study provides estimates of the preva-
lence of comorbidities such as hypertension, retinopathy,
and cardiac disease in people with T2DM, based on a
nationally representative sample. This information may be
useful to clinicians, policy makers, and entities focused on
population health management.
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